Yu Jui Kung

Jan 2, 2024 | jci.org | Brandon Lam |Yu Jui Kung |John Lin |Ssu-Hsueh Tseng

AbstractEven with the prolific clinical use of next-generation cancer therapeutics, many tumors remain unresponsive or become refractory to therapy, creating a medical need. In cancer, DCs are indispensable for T cell activation, so there is a restriction on cytotoxic T cell immunity if DCs are not present in sufficient numbers in the tumor and draining lymph nodes to take up and present relevant cancer antigens.